Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

  • chimakot chimakot Apr 29, 2013 8:38 AM Flag

    This is from today's impressive press release.

    In addition to the detailed efficacy and safety results of the ESTABLISH-2 study, which build upon the top-line results previously announced, Trius presented the results of a drug interaction clinical study demonstrating that tedizolid phosphate does not increase blood pressure when used in conjunction with vasoconstrictor drugs such as decongestants. In addition, the results of a separate clinical cardiovascular safety study showed that tedizolid is not associated with heart beat abnormalities at up to six times its effective dose, the maximum dose examined in the study. The results of both studies further support the safety profile for tedizolid. In addition, in an oral presentation, Trius provided an overview of data on an emerging class of bacterial pathogens that is resistant to linezolid (Zyvox), the only marketed drug of the same class as tedizolid. To date, these strains have proven susceptible to tedizolid

    Let's Ride!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
TSRX
13.63+0.0400(+0.29%)Sep 11 4:00 PMEDT